38609-97-1
38609-97-1
Chemical Structure
Cridanimod
- CAS No.: 38609-97-1
- Formula:C15H11NO3
- Molecular Weight:253.26
IUPAC Name: 2-(9-oxoacridin-10(9H)-yl)acetic acid
InChIKey: UOMKBIIXHQIERR-UHFFFAOYSA-N
SMILES: O=C(O)CN(C1=C2C=CC=C1)C3=CC=CC=C3C2=O
Biological Activity: Cridanimod is a potent progesterone receptor (PR) activator mediated through induction of IFNα and IFNβ expression. Cridanimod is a small-molecule immunomodulator and interferon inducer[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Cridanimod | 99.80% | Cridanimod is a potent progesterone receptor (PR) activator mediated through induction of IFNα and IFNβ expression. Cridanimod is a small-molecule immunomodulator and interferon inducer. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Cridanimod (Standard) | ≥98% | Cridanimod is a potent progesterone receptor (PR) activator mediated through induction of IFNα and IFNβ expression. Cridanimod is a small-molecule immunomodulator and interferon inducer. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Xenetic Biosciences Announces FDA Acceptance of Investigational New Drug Application to Initiate Phase 2 Clinical Trial of Virexxa® in Endometrial Cancer. AUGUST 19, 2016
- [2]. Matthew J. Carlson, et al. Cridanimod and progestin therapy in hormone-resistant endometrial cancer. Journal of Clinical Oncology, January 30, 2017.
